Bibliography
- Papers of special note have been highlighted as either of interest (●) or of considerable interest (●●) to readers.
- Wick J. The history of benzodiazepines. Consult Pharm. 2013;28:538–548.
- Ming GL, Song HJ. Adult neurogenesis in the mammalian brain: significant answers and significant questions. Neuron. 2011;70:687–702.
● Review summarizing the facts on adult neurogenesis and its importance.
- Kempermann G. Why new neurons? possible functions for adult hippocampal neurogenesis. J Neurosci. 2002;22:635–638.
- Jun HC, Hussaini SMQ, Rigby MJ, et al. Functional role of adult hippocampal neurogenesis as a therapeutic strategy for mental disorders. Neural Plast. 2012;20.
● Review on hippocampal neurogenesis as therapeutic target for CNS disorders.
- Ekdahl CT, Claasen JH, Bonde S, et al. Inflammation is detrimental for neurogenesis in adult brain. Proc Natl Acad Sci USA. 2003;100:13632–13637.
- Erickson KI, Voss MW, Prakash RS, et al. Exercise training increases size of hippocampus and improves memory. Proc Natl Acad Sci USA. 2011;108:3017–3022.
- Lee J, Duan W, Mattson MP. Evidence that brain-derived neurotrophic factor is required for basal neurogenesis and mediates, in part, the enhancement of neurogenesis by dietary restriction in the hippocampus of adult mice. J Neurochem. 2002;82:1367–1375.
- Delfani K, Janson AM, Kuhn GH, et al. Treatment of central nervous system disorders by use of PDGF or VEGF. WO2003024478A1 2003.
- Santarelli L, Saxe M, Gross C, et al. Requirement of hippocampal neurogenesis for the behavioral effects of antidepressants. Science. 2003;301:805–809
● Some common antidepressants act through stimulation of neurogenesis.
- Malberg JE, Eisch AJ, Nestler EJ, et al. Chronic antidepressant treatment increases neurogenesis in adult rat hippocampus. J Neurosci. 2000;20:9104–9110.
- Chiu F-C, Mahadik SP, Wakade CG. Antipsychotic agents stimulate neurogenesis in brain. US20030064082A1. 2003.
- Kusumi I, Boku S, Takahashi Y. Psychopharmacology of atypical antipsychotic drugs: from the receptor binding profile to neuroprotection and neurogenesis. Psychiatry Clin Neurosci. 2015;69:243–258.
● Atypical antipsychotics act through stimulation of neurogenesis.
- Kodamo M, Fujioko T, Duman RS. Chronic olanzapine or fluoxetine administration increases cell proliferation in hippocampus and prefrontal cortex of adult rat. Biol Psychiatry. 2004;56:570– 580.
- Robin NC, Agoston Z, Biechele TL, et al. Simvastatin promotes adult hippocampal neurogenesis by enhancing Wnt/beta-catenin signaling. Stem Cell Rep. 2014;2:9–17.
- Jenrow KA, Liu JG, Brown SL, et al. Combined atorvastatin and ramipril mitigate radiation-induced impairment of dentate gyrus neurogenesis. J Neurooncol. 2011;101:449–456.
- Hellerstein MK, Shankaran M The use statins to stimulate neurogenesis and to treat depression and other conditions. WO2007106862A2. 2007.
- Yang X-W, Yang C-P, Jiang L-P, et al. Indole alkaloids with new skeleton activating neural stem cells. Org Lett. 2014;16:5808–5811.
- Sompol P, Liu X, Baba K, et al. N-acetylserotonin promotes hippocampal neuroprogenitor cell proliferation in sleep-deprived mice. Proc Natl Acad Sci USA. 2011;108:8844–8849.
- McKnight SL, Pieper AA, Ready JM, et al. Pro-neurogenic compounds as therapeutic agents for the treatment of neuropsychiatric and/or neurodegenerative diseases. WO2014031986A1. 2014.
- Walker AK, Rivera PD, Wang Q, et al. The P7C3 class of neuroprotective compounds exerts antidepressant efficacy in mice by increasing hippocampal neurogenesis. Mol Psychiatry. 2015;20:500–508.
●● Development of one of the most promising class of small-molecule neurogenesis inducers.
- MacMillan KS, Naidoo J, Liang J, et al. Development of proneurogenic, neuroprotective small molecules. J Am Chem Soc. 2011;133:1428–1437.
- Latchney SE, Jaramillo TC, Rivera PD, et al. Chronic P7C3 treatment restores hippocampal neurogenesis. Neurosci Lett. 2015;591:86–92.
- Pieper AA, Xie SH, Capota E, et al. Discovery of a proneurogenic, neuroprotective chemical. Cell. 2010;142:39–51.
- Venkatraman S, Mahmood S, Mobele BI, et al. Process for preparation of piperazine derivative. WO2011028548A1. 2011.
- Ereshefsky L, English B, Johnstone J, et al. Effects of NSI-189, a neurogenic compound, on quantitative EEG (QEEG) in patients with major depressive disorder: QEEG effects, dose response relationships, and clinical outcomes. Neuropsychopharmacology. 2014;39:S353–S54.
●● Report on first small-molecule neurogenesis inducer in clinical testing, Phases Ia and Ib.
- Jagasia R, Jakob-Roetne R, Peters J-U, et al. Preparation of indol-carboxamide derivatives as neurogenic agents. WO2015036412A1. 2015.
● The evaluated patent application.
- Ceccarelli SM, Jagasia R, Jakob-Roetne R, et al. Preparation of benzisoxazoles as modulators of neurogenesis. WO2014016267A1. 2014.
- Ceccarelli SM, Jagasia R, Jakob-Roetne R, et al. Preparation of benzimidazoles as CNS active agents. WO2014053409A1. 2014.
- Ceccarelli SM, Jagasia R, Jakob-Roetne R, et al. Neurogenesis-stimulating isoquinoline derivatives. WO2014177596A1. 2014.
- Ceccarelli SM, Jagasia R, Jakob-Roetne R, et al. Preparation of 1,7-naphthyridine derivatives as neurogenesis stimulators for treatment of neurological diseases and neuropsychiatric disorders. WO2015014768A1. 2015.
- Ceccarelli SM, Jagasia R, Jakob-Roetne R, et al. Preparation of substituted 1,6-naphthyridines. WO2014079787A1. 2014.
- Ceccarelli SM, Jagasia R, Jakob-Roetne R, et al. Piperazino[1,2-a]indol-1-ones and [1,4]diazepino[1,2-a]indol-1-one as neurogenesis modulators and their preparation. WO2014023674A1. 2014.
- Schinkel AH. P-glycoprotein, a gatekeeper in the blood-brain barrier. Adv Drug Deliv Rev. 1999;36:179–194.
- Norinder U, Haeberlein M. Computational approaches to the prediction of the blood-brain distribution. Adv Drug Deliv Rev. 2002;54:291–313.
- van de Waterbeemd H, Camenisch G, Folkers G, et al. Estimation of blood-brain barrier crossing of drugs using molecular size and shape, and H-bonding descriptors. J Drug Target. 1998;6:151–165.
- Kelder J, Grootenhuis PDJ, Bayada DM, et al. Polar molecular surface as a dominating determinant for oral absorption and brain penetration of drugs. Pharm Res. 1999;16:1514–1519.